American Express Company

New York Stock Exchange
Back to all articles
Bullish +75

American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades' - Benzinga

📈 American Express reported Q1 2026 revenue of $18.91 billion, a 10% year-over-year increase that beat analyst estimates.

💳 Growth was fueled by higher card member spending, rising net interest income, and strong card fee growth.

📊 CNBC's 'Final Trades' featured American Express as a top pick from Jenny Van Leeuwen Harrington of Gilman Hill Asset Management.

🚀 Morgan Stanley analyst Cameron Mansson-Perrone raised the Live Nation price target to $200 and maintained an Overweight rating.

📈 Joshua Brown of Ritholtz Wealth Management identified Live Nation as a stock on the verge of a new 52-week high.

💊 Eli Lilly received FDA approval for EBGLYSS in atopic dermatitis, leading Rob Sechan to name it his final trade.

📉 American Express shares rose 1.6% to settle at $318.49 during the trading session.

🎢 Live Nation Entertainment shares climbed 2.9% to close at $172.33 on Thursday.

💊 Eli Lilly shares gained 2.2% to close at $1,160.95 following positive regulatory news.

Bullish Signals
  • American Express delivered a solid earnings beat with revenue reaching $18.91 billion, exceeding the consensus estimate of $18.62 billion.
  • The company demonstrated broad-based strength with growth in card balances, net interest income, and card fees simultaneously.
  • Multiple prominent market experts, including Jenny Van Leeuwen Harrington and Joshua Brown, explicitly selected American Express as a top trade or near-term winner.
  • Analyst Cameron Mansson-Perrone increased the price target for Live Nation Entertainment to $200, signaling strong institutional confidence.
  • American Express shares gained 1.6% in trading volume, reflecting immediate positive market reaction to the earnings report and analyst endorsements.
Full Analysis
American Express reported strong first-quarter 2026 results on April 23, with quarterly revenue growing 10% year-over-year to $18.91 billion, surpassing the analyst consensus of $18.62 billion. The growth was driven by higher card member spending, increased net interest income, expanding card balances, and robust card fee growth. In a segment from CNBC's 'Final Trades,' multiple market experts highlighted American Express as a top pick. Rob Sechan of NewEdge Wealth selected Eli Lilly as his final trade following FDA approval for its atopic dermatitis drug EBGLYSS, while Joshua Brown of Ritholtz Wealth Management noted Live Nation Entertainment is approaching a new 52-week high. Analyst sentiment remains positive across the board. Morgan Stanley analyst Cameron Mansson-Perrone maintained an Overweight rating on Live Nation and raised its price target from $185 to $200. Consequently, shares for American Express rose 1.6% to close at $318.49, while Live Nation climbed 2.9% to $172.33 and Eli Lilly gained 2.2% to $1,160.95.